A Phase 1/2, Observer-blind, Randomized, Placebo-controlled Multi-country Study to Assess Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Latest Information Update: 24 Apr 2024
At a glance
- Drugs GSK 4348413A (Primary)
- Indications Gonorrhoea
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 19 Apr 2024 Planned End Date changed from 9 Jun 2025 to 23 May 2025.
- 19 Apr 2024 Planned primary completion date changed from 9 Jun 2025 to 23 May 2025.
- 19 Apr 2024 Status changed from recruiting to active, no longer recruiting.